Monopar Therapeutics (MNPR) Interest & Investment Income (2022 - 2026)
Monopar Therapeutics (MNPR) posted Interest & Investment Income of -$65763.0 for Q3 2025, down 108.42% sequentially from $780769.0 in Q2 2025, and down 166.2% YoY from $99344.0 in Q3 2024.
Monopar Therapeutics (MNPR) Interest & Investment Income (2022 - 2026) Analysis & Trends
Monopar Therapeutics has reported Interest & Investment Income for 4 years, with the latest figure at -$65763.0 in Q3 2025.
- Quarterly Interest & Investment Income fell 166.2% year-over-year to -$65763.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $814696.0 (up 249.29% YoY) and the FY2023 annual result came in at $800998.0, up 27.12% from the prior year.
- Interest & Investment Income slipped to -$65763.0 in Q3 2025 per MNPR's latest filing, from $780769.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $800998.0 in Q4 2023 and troughed at -$65763.0 in Q3 2025.
- A 4-year average of $217561.3 and a median of $33645.0 in 2023 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 31846.36% in 2025, down 166.2% in 2025.
- Over 4 years, Interest & Investment Income stood at $630113.0 in 2022, then climbed by 27.12% to $800998.0 in 2023, then plunged by 87.6% to $99344.0 in 2024, then tumbled by 166.2% to -$65763.0 in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$65763.0, $780769.0, and $346.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Sep 30, 2025 | -65,763.00 |
| Jun 30, 2025 | 780,769.00 |
| Mar 31, 2025 | 346.00 |
| Sep 30, 2024 | 99,344.00 |
| Jun 30, 2024 | 2,444.00 |
| Mar 31, 2024 | 19,198.00 |
| Dec 31, 2023 | 800,998.00 |
| Sep 30, 2023 | 112,260.00 |
| Jun 30, 2023 | -20,180.00 |
| Mar 31, 2023 | 33,645.00 |
| Dec 31, 2022 | 630,113.00 |